熱門資訊> 正文

Abeona以1.55亿美元的价格出售罕见儿科疾病PRV

2025-07-02 23:47

Shares of Abeona Therapeutics (NASDAQ:ABEO) rose on Wednesday after the company said that it has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV), earning $155M on June 27.
The company reported that, after accounting for the sale, its cash, cash equivalents, restricted cash, and short-term investments totaled about $225M as of June 30, 2025.
In April 2025, the U.S. FDA awarded Abeona the PRV following the approval of its gene therapy, Zevaskyn, which is used to treat wounds in both adult and pediatric patients with recessive dystrophic epidermolysis bullosa.
ABEO stock up 8% today.

More on Abeona Therapeutics

Is Abeona Therapeutics' Zevaskyn Worth $3.1m Per Treatment, Or Will Krystal Biotech Remain The Market Leader?
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)
Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript
Abeona Therapeutics added to U.S. Small-cap Russell 2000 and Russell 3000 Indexes
Abeona targets treating 10–14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。